WebDisclosure WebDisclosure
Basculer en Français
10825 Companies
234834 Keywords
163669 Articles
125673 Press releases
Headlines Articles Press releases OBI Pharma USA, Inc. Remove
  1. Home
  2. Companies
  3. OBI Pharma USA, Inc.
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 04/15/2026 at 10:45, 3 months 27 days ago

    OBI Pharma Presents Ten New Poster Sessions at AACR 2026

    Cancer Treatment ADC Technology OBI Pharma Tumor Heterogeneity GlycOBI® Platform
  • BRIEF

    published on 04/15/2026 at 10:45, 3 months 27 days ago

    OBI Pharma présente dix nouvelles sessions d'affiches à l'AACR 2026

    Traitement Du Cancer Technologie ADC OBI Pharma Hétérogénéité Tumorale Plateforme GlycOBI®
  • PRESS RELEASE

    published on 04/15/2026 at 10:40, 3 months 27 days ago

    OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies

    OBI Pharma showcases advancements in ADC technology at AACR 2026, highlighting GlycOBI platform. Poster presentations feature OBI-902, OBI-904, OBI-201, OBI-221, and novel Obrion technology
    Poster Presentations ADC Technology AACR 2026 OBI Pharma GlycOBI Platform
    Logo of OBI Pharma USA, Inc.
Accesswire
  • Published on 08/12/2026 at 15:00, 34 minutes ago

    Karbon-X and Core Energy Sign Letter of Intent to Explore Commercial EV Charging Infrastructure in South America

  • Published on 08/12/2026 at 14:45, 49 minutes ago

    Lobe Sciences Ltd. Announces Non-Brokered Private Placement

  • Published on 08/12/2026 at 14:30, 1 hour 4 minutes ago

    Recent Corporate Events Recap

  • Published on 08/12/2026 at 14:00, 1 hour 34 minutes ago

    International Battery Metals Appoints Scott Colangelo to Board of Directors

  • Published on 08/12/2026 at 13:55, 1 hour 39 minutes ago

    Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study

View all ACCESSWIRE
EQS Group
  • Published on 08/12/2026 at 15:28, 5 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: easyJet plc

  • Published on 08/12/2026 at 15:27, 6 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: SEGRO plc

  • Published on 08/12/2026 at 15:27, 7 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: LondonMetric Property plc

  • Published on 08/12/2026 at 15:25, 8 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: Bodycote plc

  • Published on 08/12/2026 at 15:25, 9 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: Picton Property Income Limited

View all EQS
Les Echos
  • Published on 08/11/2026 at 17:45, 21 hours 49 minutes ago

    DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026

  • Published on 08/11/2026 at 17:40, 21 hours 54 minutes ago

    Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions

  • Published on 08/10/2026 at 18:00, 1 day 21 hours ago

    AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026

  • Published on 08/10/2026 at 18:00, 1 day 21 hours ago

    AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026

  • Published on 08/10/2026 at 17:45, 1 day 21 hours ago

    Weekly share buyback

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2026 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy